J Korean Ophthalmol Soc.  2010 Jun;51(6):860-864. 10.3341/jkos.2010.51.6.860.

The Short-term Effect of Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy

Affiliations
  • 1Department of Ophthalmology, Konyang University, Myung-Gok Eye Research Institute, Kim's Eye Hospital, Seoul, Korea. retinalee@kimeye.com

Abstract

PURPOSE
To determine whether intravitreal bevacizumab is effective for the treatment of central serous chorioretinopathy.
METHODS
We retrospectively examined 42 eyes after intravitreal bevacizumab (1.25 mg) injection for central serous chorioretinopathy. After 1 month, improvement of vision and change in sensory retinal detachment were evaluated with a fundus examination and optical coherence tomography.
RESULTS
The mean duration of symptoms was 3.9+/-2.31 months. After intravitreal bevacizumab injection, mean best corrected visual acuity improved from 0.53+/-0.31 to 0.72+/-0.29 at 1 month. In addition, neurosensory retinal detachment disappeared in 32 patients (76.2%). Five patients among ten who did not show improvement of neurosensory retinal detachment underwent reinjection of bevaczumab, and three of those reinjected showed the resolution of neurosensory retinal detachment at another 1 month. No improvement was seen among the patients who did not undergo reinjection.
CONCLUSIONS
Intravitreal bevacizumab injection appears to have a short-term benefit for the treatment of central serous chorioretinopathy.

Keyword

Bevacizumab; Central serous chorioretinopathy

MeSH Terms

Antibodies, Monoclonal, Humanized
Central Serous Chorioretinopathy
Eye
Humans
Retinal Detachment
Retrospective Studies
Tomography, Optical Coherence
Vision, Ocular
Visual Acuity
Bevacizumab
Antibodies, Monoclonal, Humanized
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr